Danish biotech Bavarian Nordic anticipates a boost in biodefense funding by the incoming U.S. administration despite concerns ...
“Honestly, I’m quite alarmed by what we see in the US now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN ...
“Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN on Wednesday. “Patients who believe that they’re getting access to a ...
In a pivotal stride to address the growing AFib epidemic, OMRON Healthcare today announced the U.S. Food and Drug ...
Novo Nordisk President and CEO Lars Fruergaard Jorgensen, shown testifying on Capitol Hill in September, is warning about potential risks from compounded versions of the drug semaglutide.
uk.investing.com on MSN44m
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bidHalozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
The FDA has granted a de novo clearance to a wearable device—with a form factor you’re familiar with—that can check patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback